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Abstract
In the last century mercury levels in the global environment have tripled
as a result of increased pollution from industrial, occupational, medicinal
and domestic uses [1]. Glutathione is known to be the main agent responsible
for the excretion of mercury (we refer to [41], [38] and [35]). It has also been
shown that mercury inhibits glutathione synthetase (an enzyme acting in the
synthesization of Glutathione), therefore leading to decreased glutathione
levels (we refer to [41], [34], [11] and [13]). Mercury also interferes with
the production of heme in the porphyrin pathway [27]. Heme is needed for
biological energy production and ability to detox organic toxins via the P450
enzymes [19]. The purpose of this paper is to show that body’s response
to mercury exposure is hysteretic, i.e. when this feedback of mercury on
its main detoxifying agents is strong enough then mercury body burden
has two points of equilibrium: one with normal abilities to detoxify and
low levels of mercury and one with inhibited abilities to detoxify and high
levels of mercury. Furthermore, a small increase of body’s mercury burden
may not be sufficient to trigger observable neurotoxic effects but it may be
sufficient to act as a switch leading to an accumulation of mercury in the
body through environmental exposure until its toxicity becomes manifest.
1 The model
Writing C the mercury body burden a simple model for the evolution of C with
respect to time can be described by the following ordinary differential equation.
dC
dt
= µ− k(C)C (1)
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In equation (1), µ stands for the rate of exposure of the body to mercury. k(C)C
stands for the detoxification rate. As an instance of chronic exposure, recall that
the intra oral air concentration in mercury is of the order of 2µg/m3 without dental
amalgam and 20µg/m3 with dental amalgams [33]. It has also been shown that
dental amalgam filings in pregnant rats can be a prime source of exposure of fetal
tissues to mercury [46].
Although equation (1) is a toy model we believe that it captures the main
mechanism involved in mercury exposure. This toy model is based on the following
assumptions:
• The excretion rate of mercury is proportional to the mercury body burden
and we write k(C) the proportionality constant.
• The proportionality constant k(C) is a decreasing function of the mercury
burden C modeling the inhibition of organs ability to detoxify by mercury.
The model introduced in this paper is oversimplified but we believe that the
associated switch mechanism could be of some relevance in the analysis of mercury
toxicity.
Observe that one has to distinguish two main factors in mercury toxicity. The
first one (addressed in this paper) is the total amount of mercury accumulated in
the body. The second one (not addressed in this paper), is the mercury retention
effects, i.e. the toxicity of a given value of mercury body burden (see [20], [10], [9]
and the references therein).
• Low levels of mercury lead to aberrant porphyrin profile, the major product
of the porphyrin pathway is heme and it is needed for biological energy
production and ability to detoxify organic toxins via the P450 enzymes.
• Genetic susceptibilities that account for susceptibility to heavy metal toxici-
ties (such as polymorphism in the CPOX4 or APO-E genes) are an important
factor affecting excretion rates.
• Genetic variations of Apolipoprotein E (APO-E) ([19], [7], [18]) don’t play
a major role in mercury excretion but play a role in mercury retention ef-
fects by altering the detoxification abilities of the Central Nervous System
by impacting the percentage of the total mercury body burden trapped in
the cerebrospinal system. Hence although being an APO-E4 carrier won’t
significantly impact excretion rates it increases the susceptibility Alzheimer’s
disease ([19], [18]) by increasing the relative percentage of mercury withheld
in the central nervous system.
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This being said, it is important to observe that although genetic variations
may alter excretion rates (k(C) would in practice depend on genetic susceptibili-
ties), it would not explain a feed-back mechanism. Mercury is primarily excreted
bound to glutathione ([41], [38] and [35]) and mercury can inhibit the production
of glutathione [13] ([41], [34], [11] and [13]). We will show that through this feed-
back mechanism, very small doses of mercury cause a major breakdown of the
detoxification pathway.
To simplify the presentation we will assume that k(C) has the following form




where k0 is the detoxification rate at low levels of mercury and β is a constant
between 0 and 1 indicating the decrease of the proportionality constant k(C) under
levels of mercury beyond C0(1− β). Thus C0 is a positive parameter and C0(1−
β) is a constant indicating a critical level of mercury beyond which Glutathione
production is minimal. Figure 1(a) shows how k(C) would vary as a function of
C in this model.
(a) k(C) versus C. (b) k(C)C versus C.
Figure 1: k(C) and k(C)C versus C.
One should observe that the phenomenon described here is independent of the
particular choice of k(C) and is solely based on the non monotonicity of k(C)C
with respect to C as in figure 1(b).
The equilibrium points for body mercury burden are solutions of the following
equation





















Let us write Clow < Cunstable < Chigh those equilibrium points. Thus the dynamic
of the body mercury burden can be divided into two classes.
(a) Direction fields of mercury body
burden.
(b) Body burden is initially 0 with a
low rate of exposure then at time 2
the body burden is increased in one
moment.
Figure 2: Mercury burden dynamic.
Unique equilibrium point. This class is characterized by the fact that the
chronic exposure to mercury µ is above the value k0C0
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or below the value β(1 −
β)k0C0. In this dynamic C(t) will converge to the unique solution of (4) as t→∞.
Bistable equilibrium points. This class is characterized by the fact that β < 1
2
(the decrease of k(C) under high levels of mercury is at least 50%) and that
the chronic exposure to mercury µ is below the value k0C0
4
and above the value
β(1−β)k0C0. In this case if C(0) ∈ (0, Cunstable) then as t→∞, C(t) will converge
to Clow. If C(0) > Cunstable then C(t) will converge to Chigh as t→∞. Cunstable is
an unstable equilibrium point. We refer to figure 2(a). Observe also that in this
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situation a high mercury body burden can be induced by exposing the organism
to a given small amount of mercury in a short lapse of time (see figure 2(b)).
Experimental detoxification rates. It would be interesting to obtain constant
rates that apply to elemental Hg, inorganic Hg, and organic types of Hg. While
[43] contains excretion rate those rates needs to be put into correspondence with
total body burden to infer the experimental estimation of the curve k(C)C. Such
experimental data would be very valuable since it would allow us to compute the
value Cunstable−Clow (which may strain dependent) which is the amount of mercury
leading to an activation of the switch mechanism if the body is exposed to it in
one time.
Observe also that one could elaborate more sophisticated models where differ-
ent organs have different detoxification rate (depending as well upon the chemical
form of the mercury). Such models would put into evidence the biphasic blood
detoxification rates for methyl mercury (with average half periods of 7-8 hours
and 52 days). It is important to observe that the mechanism involved in the lat-
ter biphasic behavior (trapping of methyl-mercury by organs which are slow to
detoxify) is different from one involved in this paper (inhibition of the ability to
detoxify).
2 Interpretation and predictions.
According to the model presented in this paper, a transition from the low levels of
mercury body burden to the high levels of mercury body burden can be induced
by increasing the mercury body burden in a brief period of time (increasing C
through in a brief period of time) or increasing the rate of exposure (µ) over a
long enough period of time. It is important to observe that to reach high levels of
mercury body burden Chigh it is enough to increase the body burden by an amount
Cunstable − Clow which can be much smaller than Chigh − Clow (see figure 2(b)).
Observe that a prediction of our model is that once the metabolism is in the
basin of attraction of inhibited abilities to detoxify it will start accumulating not
only mercury, but also other heavy metals. Furthermore to induce a transition
from inhibited abilities to detoxify to the basin of attraction of normal abilities
to detoxify one would have to reduce the body mercury burden by an amount
Chigh − Cunstable. It is important to observe that a transition from the low levels
of mercury equilibrium point to the high levels of mercury equilibrium point can
be induced by increasing the body mercury burden by an amount much smaller
than levels corresponding to the difference between high levels and low levels of
mercury burden but to reverse the process one would have lower body’s mercury
burden by a large amount.
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(a) Mercury body burden. (b) Excretion rate.
Figure 3: At time 3 the rate of exposure is increased by ∆µ < ∆µc.
3 Impact of an increase of the exposure rate µ.
In this section the assumptions behind the model are the following: at time zero
the body burden is assumed to be zero, and the rate of exposure is assumed
fixed. Then time three the rate of exposure µ is increased by a given amount
∆µ. We observe that if ∆µ is smaller than a critical value∆µc (figure 3) then the
effect effect is a small increase of the total mercury body burden (figure 3(a)) and
a corresponding increase of the rate of excretion of mercury (figure 3(b)). The
mercury body burden remains on the equilibrium point associated to low levels of
mercury and normal abilities to detoxify.
If ∆µ is larger than the critical value∆µc (figure 4 then the effect is a large
accumulation of mercury in the body (figure 4(a)). The rate of excretion (figure
4(b)) starts increasing due the increase of mercury exposure, it reaches a maxi-
mum value then starts decreasing due to inhibited abilities to detoxify. Mercury
accumulates in the organs until the equilibrium points corresponding to a high
mercury burden is reached then the excretion rate increases again to match the
exposure rate. In this second scenario the body burden bifurcates from low levels
of mercury and normal abilities to detoxify to high levels of mercury and inhibited
abilities to detoxify.
This theoretical observation based on our toy model is to be put in relation with
s recent study [12] showing that after placing amalgams on children the urinary
excretion of mercury starts increasing, reaches a peak at year 2, then drop over
40% in the next 5 years to the point where the error bars on the amalgam bearers
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(a) Mercury body burden. (b) Excretion rate.
Figure 4: At time 3 the rate of exposure is increased by ∆µ > ∆µc.
vs controls overlap. This drop in mercury excretion has been interpreted by the
authors of [12] as proof of safety of dental amalgams. An other interpretation
put forward in [20] is that children when exposed to mercury vapor for extended
periods of time, slowly lose the ability to excrete mercury in their urine. Figure 4
show that an increase of the rate of exposure switch off the ability to detoxify and
lead to a drop in the excretion rate after an initial period of increase.
4 Mercury, a toxic time bomb [1].
Mercury may be involved in several neurological disorders, where high mercury ex-
posure at one moment or continuously could result in a reduced ability to detoxify
(reduced k(C)).
First observe that toxic and neurotoxic effects of heavy metals [26] and in
particular mercury [29] are well known. We refer to [6] for a review of human
exposure to mercury and to [42] for an instance of acute exposure (Minamata
disease).
Growth delay, reduced locomotion, exaggerated response to novelty, and densely
packed, hyperchromic hippocampal neurons with altered glutamate receptors and
transporters can be induced in mice following thimerosal challenges that mimic
routine childhood immunizations [23]. Thimerosal (ethylmercury) has been used
as a preservative in vaccines since the 1930s [31]. It has been shown in infant
monkeys that [4] Thimerosal crosses the blood-brain barrier and transforms into
inorganic mercury in the central nervous system. For strong evidences of the link
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between autism and mercury we refer to [17], [37] and [39].
Reduced levels of mercury have been found in first baby haircuts of autistic
children indicating their inability to excrete mercury [22]. It has been observed in
mice [23] that the sensitivity to thimerosal is strain dependent, this may indicate
that detoxification abilities in the absence of mercury are already low in those
strains or that the barrier Cunstable − Clow is small enough in those strains to be
crossed through injections of low amounts of ethylmercury.
We refer to [40] and [2] for the psychometric evidence that dental amalgam
mercury may be an etiological factor in schizophrenia. In cerebrospinal fluid of
drug-free schizophrenic patients, a significant decrease in the level of total glu-
tathione has been observed as compared to controls [14].
We refer to [5] and [45] for the association between body burden mercury level
and Parkinson’s disease.
There is a significantly greater proportion of males than females affected by
schizophrenia [36], Parkinson’s disease [16] or autism [34], [11]. This has to be
compared to the fact that at low levels of mercury, testosterone is known to enhance
the neurotoxicity of mercury whereas oestrogen has protective properties [44].
It has been observed that blood mercury levels were more than two-fold higher
in Alzheimer’s disease patients as compared to control groups [21] (we also refer to
[15]). It is also known [28] that seven of the characteristic markers of Alzheimer’s
disease can be produced in normal brain tissues, or cultures of neurons, by the
addition of extremely low levels of mercury.
It is interesting to observe in that context that chelation therapies have been
proposed for Parkinson’s disease [8], Alzheimer’s disease [30] and autism [24]. Fur-
thermore high levels of mercury have been detected in autistic children following
chelation therapy with DMSA [3], [25]. Furthermore urine excretion of mercury
after DMPS challenge has been shown to be proportional to whole body burden
before chelation [32].
A support of the detoxification pathway without the use of DMSA or DMPS
has also been observed to lead a very significant increase of the rate of excretion of
mercury (and other heavy metals) [47]. A strong link between detoxification and
recovery from autism has been observed [24], [47].
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